Earnings Call Summary | Senseonics(SENS.US) Q1 2024 Earnings Conference
Earnings Call Summary | Senseonics(SENS.US) Q1 2024 Earnings Conference
The following is a summary of the Senseonics Holdings, Inc. (SENS) Q1 2024 Earnings Call Transcript:
以下是Senseonics Holdings, Inc.（SENS）2024年第一季度業績電話會議記錄摘要：
Financial Performance:
財務業績：
Senseonics' Q1 revenue totaled $5.1 million, marking a growth rate of 22% compared to the previous year, mainly due to high fixed manufacturing costs.
U.S. sales for Q1 amounted to $3.7 million and non-U.S. sales were $1.4 million.
Senseonics第一季度的收入總額爲510萬美元，與去年同期相比增長了22％，這主要是由於高昂的固定制造成本。
第一季度美國銷售額爲370萬美元，非美國銷售額爲140萬美元。
Business Progress:
業務進展：
Significant advances have been made in the company's commercial efforts, such as a growing patient base and fruitful collaboration with Mercy Health System.
Progress has been made in Senseonics' product pipeline with the establishment of the Eversense Remote Patient Monitoring (RPM) program along with achieving the iCGM designation from the FDA.
Senseonics has submitted the 510(k) for their 365-day product and is planning to make further strides through 2024.
It is projected that new patient additions will grow by 150% year-over-year aligning with previous estimates.
A collaborative agreement with Mercy Health System plans to introduce its Eversense CGM product to Mercy's at-risk patient base estimated to be around 30,000, providing both device and RPM sector benefits to Senseonics.
The approval process for the Eversense 365-day product is on track, with ongoing discussion with Medicare and commercial pay actors.
Negotiations for integrating with insulin pump manufacturers have begun following the receipt of the iCGM designation from the FDA.
該公司的商業努力取得了重大進展，例如患者群的擴大以及與Mercy Health System的卓有成效的合作。
隨着Eversense遠程患者監護（RPM）計劃的建立以及獲得美國食品藥品管理局的iCGM認證，Senseonics的產品線取得了進展。
Senseonics已經提交了爲期365天的產品的510（k），並計劃在2024年之前取得進一步的進展。
預計新增患者將同比增長150％，與先前的估計一致。
與Mercy Health System簽訂的合作協議計劃向Mercy的高危患者群體推出其Eversense CGM產品，估計約爲3萬人，爲Senseonics提供設備和RPM領域的好處。
Eversense365天產品的批准程序已步入正軌，與醫療保險和商業薪酬參與者的討論仍在進行中。
在獲得美國食品藥品管理局的iCGM認證後，與胰島素泵製造商整合的談判已經開始。
More details: Senseonics IR
更多詳情： Senseonics 紅外
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：欲了解更多詳情，請訪問投資者關係網站。本文僅供投資者參考，不構成任何投資建議。
譯文內容由第三人軟體翻譯。